Latest:
Dr. D'Cunha on Surgical Options for High-Risk Patients With Lung Cancer
Jonathan D'Cunha, MD, PhD, FACS, discusses surgical options for high-risk patients with lung cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Jonathan E. Brammer, MD
Latest:
Rapid Readouts: Interim Analysis Results From the Phase 2 PRIMO Trial in R/R Peripheral T-Cell Lymphoma
Jonathan E. Brammer, MD, reports data presented at the 2021 American Society of Hematology Annual Meeting regarding interim analysis study results from the phase 2 PRIMO trial evaluating the use of duvelisib monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma.
Jonathan L. Wright, MD, MS, FACS
Latest:
Dr. Wright on Frontline Considerations in Locally Advanced Bladder Cancer
Jonathan L. Wright, MD, MS, FACS, medical director of the University of Washington Medical Center Urology Clinic, associate professor of urology at University of Washington, and affiliate investigator at the Fred Hutchinson Cancer Research Center, discusses frontline considerations in patients with locally advanced, muscle-invasive bladder cancer.
Jonathan Ledermann, MD, PhD
Latest:
Dr. Ledermann on PARP Inhibitors in Maintenance Therapy for Ovarian Cancer
Jonathan Ledermann, MD, professor of medical oncology at UCL Cancer Institute in London, discusses the growing use of PARP inhibitors in maintenance therapy for ovarian cancer in an interview during the 2019 SGO Annual Meeting.
Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center
Latest:
Charting the Future: Key Therapies for Managing EGFR-Mutant NSCLC
This episode focuses on exploring additional therapeutic options for managing previously treated advanced or metastatic EGFR-mutated NSCLC, highlighting strategies to optimize patient survival across various stages of disease progression.
Jonathan S. Berek, MD
Latest:
Dr. Berek Discusses the Impact of PARP Inhibitors on Ovarian Cancer
Jonathan S. Berek, MD, MMS, Laurie Kraus Lacob Professor, Stanford University School of Medicine, director, Stanford Women’s Cancer Center, senior advisor, Stanford Cancer Institute, discusses the impact of PARP inhibitors on the treatment landscape of ovarian cancer.